Stangel M - Search Results

1

Varicella zoster virus infections in neurological patients: a clinical study.

Skripuletz T, Pars K, Schulte A, Schwenkenbecher P, Yildiz Ö, Ganzenmueller T, Kuhn M, Spreer A, Wurster U, Pul R, Stangel M, Sühs KW, Trebst C. Skripuletz T, et al. Among authors: stangel m. BMC Infect Dis. 2018 May 25;18(1):238. doi: 10.1186/s12879-018-3137-2. BMC Infect Dis. 2018. PMID: 29801466 Free PMC article.

2

Comparison of intravenous immunoglobulin preparations on microglial function in vitro: more potent immunomodulatory capacity of an IgM/IgA-enriched preparation.

Pul R, Nguyen D, Schmitz U, Marx P, Stangel M. Pul R, et al. Among authors: stangel m. Clin Neuropharmacol. 2002 Sep-Oct;25(5):254-9. doi: 10.1097/00002826-200209000-00005. Clin Neuropharmacol. 2002. PMID: 12410056

3

[Chemokine--possible new options for the treatment of multiple sclerosis].

Trebst C, Ransohoff RM, Windhagen A, Stangel M. Trebst C, et al. Among authors: stangel m. Nervenarzt. 2003 Oct;74(10):850-7. doi: 10.1007/s00115-003-1571-9. Nervenarzt. 2003. PMID: 14551688 Review. German.

4

Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.

Marckmann S, Wiesemann E, Hilse R, Trebst C, Stangel M, Windhagen A. Marckmann S, et al. Among authors: stangel m. Clin Exp Immunol. 2004 Dec;138(3):499-506. doi: 10.1111/j.1365-2249.2004.02624.x. Clin Exp Immunol. 2004. PMID: 15544628 Free PMC article.

5

[Cannabinoids in multiple sclerosis -- therapeutically reasonable?].

Trebst C, Stangel M. Trebst C, et al. Among authors: stangel m. Fortschr Neurol Psychiatr. 2005 Aug;73(8):463-9. doi: 10.1055/s-2004-830119. Fortschr Neurol Psychiatr. 2005. PMID: 16052440 Review. German.

6

[Concepts of lesion development in multiple sclerosis. Current approaches and clinical-therapeutic implications ].

Trebst C, Wiendl H, Stangel M. Trebst C, et al. Among authors: stangel m. Nervenarzt. 2006 Feb;77(2):158, 160-2, 164. doi: 10.1007/s00115-005-1994-6. Nervenarzt. 2006. PMID: 16160810 Review. German.

7

Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis.

Trebst C, Stangel M. Trebst C, et al. Among authors: stangel m. Curr Pharm Des. 2006;12(2):241-9. doi: 10.2174/138161206775193118. Curr Pharm Des. 2006. PMID: 16454740 Review.

8

Remyelination strategies: new advancements toward a regenerative treatment in multiple sclerosis.

Stangel M, Trebst C. Stangel M, et al. Curr Neurol Neurosci Rep. 2006 May;6(3):229-35. doi: 10.1007/s11910-006-0010-2. Curr Neurol Neurosci Rep. 2006. PMID: 16635432 Review.

9

Basic principles of intravenous immunoglobulin (IVIg) treatment.

Stangel M, Pul R. Stangel M, et al. J Neurol. 2006 Sep;253 Suppl 5:V18-24. doi: 10.1007/s00415-006-5003-1. J Neurol. 2006. PMID: 16998749 Review.

10

Expression of chemokine receptors on peripheral blood mononuclear cells of patients with immune-mediated neuropathies treated with intravenous immunoglobulins.

Trebst C, Brunhorn K, Lindner M, Windhagen A, Stangel M. Trebst C, et al. Among authors: stangel m. Eur J Neurol. 2006 Dec;13(12):1359-63. doi: 10.1111/j.1468-1331.2006.01521.x. Eur J Neurol. 2006. PMID: 17116220

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

365 results

Search Page

Filters